Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension

Ahmed A. Elmarakby, Jeffrey E. Quigley, Jeffrey J. Olearczyk, Aarthi Sridhar, Anthony K. Cook, Edward W. Inscho, David M. Pollock, John D. Imig

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The present study was designed to determine whether chemokine receptor 2b (CCR2b) contributes to the development of renal injury in salt-sensitive angiotensin II (ANG) hypertension. Rats were infused with ANG and fed a high-salt diet (HS) for 14 days. Rats were divided into 4 groups: HS; HS administered the CCR2b antagonist, RS102895; Ang/HS hypertensive; and Ang/HS hypertensive administered RS102895. CCR2b inhibition slowed the progression of blood pressure elevation during the first week of ANG/HS hypertension; however, it did not alter blood pressure in the HS group. At 2 weeks, arterial pressure was not significantly different between ANG/HS and ANG/HS hypertensive rats administered RS102895. Renal cortical nuclear factor κB activity increased in ANG/HS hypertension compared with the HS group (0.11±0.006 versus 0.08±0.003 ng of activated nuclear factor κB per microgram of protein), and RS102895 treatment lowered nuclear factor κB activity in ANG/HS hypertension (0.08±0.005 ng of activated nuclear factor κB per microgram of protein). Renal tumor necrosis factor-α and intercellular adhesion molecule-1 expression increased, and Cyp2c23 expression decreased in ANG/HS hypertension compared with the HS group, and CCR2b inhibition reduced tumor necrosis factor-α and intercellular adhesion molecule-1 and increased Cyp2c23 expression. Histological immunostaining revealed increased renal monocyte and macrophage infiltration in ANG/HS hypertensive rats with decreased infiltration in rats receiving RS102895 treatment. Albuminuria and cortical collagen staining also increased in ANG/HS hypertensive rats, and RS102895 treatment lowered these effects. Afferent arteriolar autoregulatory responses to increasing renal perfusion pressure were blunted in ANG/HS hypertension, and RS102895 treatment improved this response. These data suggest that CCR2b inhibition protects the kidney in hypertension by reducing inflammation and delaying the progression of hypertension.

Original languageEnglish (US)
Pages (from-to)1069-1076
Number of pages8
JournalHypertension
Volume50
Issue number6
DOIs
StatePublished - Dec 1 2007

Fingerprint

Chemokine Receptors
Angiotensin II
Salts
Hypertension
Kidney
Diet
Intercellular Adhesion Molecule-1
Tumor Necrosis Factor-alpha
Albuminuria

Keywords

  • Angiotensin
  • CCR2b
  • Chemokines
  • Hypertension
  • Inflammation
  • Kidney
  • MCP-1

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Elmarakby, A. A., Quigley, J. E., Olearczyk, J. J., Sridhar, A., Cook, A. K., Inscho, E. W., ... Imig, J. D. (2007). Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension. Hypertension, 50(6), 1069-1076. https://doi.org/10.1161/HYPERTENSIONAHA.107.098806

Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension. / Elmarakby, Ahmed A.; Quigley, Jeffrey E.; Olearczyk, Jeffrey J.; Sridhar, Aarthi; Cook, Anthony K.; Inscho, Edward W.; Pollock, David M.; Imig, John D.

In: Hypertension, Vol. 50, No. 6, 01.12.2007, p. 1069-1076.

Research output: Contribution to journalArticle

Elmarakby, AA, Quigley, JE, Olearczyk, JJ, Sridhar, A, Cook, AK, Inscho, EW, Pollock, DM & Imig, JD 2007, 'Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension', Hypertension, vol. 50, no. 6, pp. 1069-1076. https://doi.org/10.1161/HYPERTENSIONAHA.107.098806
Elmarakby, Ahmed A. ; Quigley, Jeffrey E. ; Olearczyk, Jeffrey J. ; Sridhar, Aarthi ; Cook, Anthony K. ; Inscho, Edward W. ; Pollock, David M. ; Imig, John D. / Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension. In: Hypertension. 2007 ; Vol. 50, No. 6. pp. 1069-1076.
@article{8a396a51c4d54ef0aa51ded432d0a242,
title = "Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension",
abstract = "The present study was designed to determine whether chemokine receptor 2b (CCR2b) contributes to the development of renal injury in salt-sensitive angiotensin II (ANG) hypertension. Rats were infused with ANG and fed a high-salt diet (HS) for 14 days. Rats were divided into 4 groups: HS; HS administered the CCR2b antagonist, RS102895; Ang/HS hypertensive; and Ang/HS hypertensive administered RS102895. CCR2b inhibition slowed the progression of blood pressure elevation during the first week of ANG/HS hypertension; however, it did not alter blood pressure in the HS group. At 2 weeks, arterial pressure was not significantly different between ANG/HS and ANG/HS hypertensive rats administered RS102895. Renal cortical nuclear factor κB activity increased in ANG/HS hypertension compared with the HS group (0.11±0.006 versus 0.08±0.003 ng of activated nuclear factor κB per microgram of protein), and RS102895 treatment lowered nuclear factor κB activity in ANG/HS hypertension (0.08±0.005 ng of activated nuclear factor κB per microgram of protein). Renal tumor necrosis factor-α and intercellular adhesion molecule-1 expression increased, and Cyp2c23 expression decreased in ANG/HS hypertension compared with the HS group, and CCR2b inhibition reduced tumor necrosis factor-α and intercellular adhesion molecule-1 and increased Cyp2c23 expression. Histological immunostaining revealed increased renal monocyte and macrophage infiltration in ANG/HS hypertensive rats with decreased infiltration in rats receiving RS102895 treatment. Albuminuria and cortical collagen staining also increased in ANG/HS hypertensive rats, and RS102895 treatment lowered these effects. Afferent arteriolar autoregulatory responses to increasing renal perfusion pressure were blunted in ANG/HS hypertension, and RS102895 treatment improved this response. These data suggest that CCR2b inhibition protects the kidney in hypertension by reducing inflammation and delaying the progression of hypertension.",
keywords = "Angiotensin, CCR2b, Chemokines, Hypertension, Inflammation, Kidney, MCP-1",
author = "Elmarakby, {Ahmed A.} and Quigley, {Jeffrey E.} and Olearczyk, {Jeffrey J.} and Aarthi Sridhar and Cook, {Anthony K.} and Inscho, {Edward W.} and Pollock, {David M.} and Imig, {John D.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.107.098806",
language = "English (US)",
volume = "50",
pages = "1069--1076",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension

AU - Elmarakby, Ahmed A.

AU - Quigley, Jeffrey E.

AU - Olearczyk, Jeffrey J.

AU - Sridhar, Aarthi

AU - Cook, Anthony K.

AU - Inscho, Edward W.

AU - Pollock, David M.

AU - Imig, John D.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - The present study was designed to determine whether chemokine receptor 2b (CCR2b) contributes to the development of renal injury in salt-sensitive angiotensin II (ANG) hypertension. Rats were infused with ANG and fed a high-salt diet (HS) for 14 days. Rats were divided into 4 groups: HS; HS administered the CCR2b antagonist, RS102895; Ang/HS hypertensive; and Ang/HS hypertensive administered RS102895. CCR2b inhibition slowed the progression of blood pressure elevation during the first week of ANG/HS hypertension; however, it did not alter blood pressure in the HS group. At 2 weeks, arterial pressure was not significantly different between ANG/HS and ANG/HS hypertensive rats administered RS102895. Renal cortical nuclear factor κB activity increased in ANG/HS hypertension compared with the HS group (0.11±0.006 versus 0.08±0.003 ng of activated nuclear factor κB per microgram of protein), and RS102895 treatment lowered nuclear factor κB activity in ANG/HS hypertension (0.08±0.005 ng of activated nuclear factor κB per microgram of protein). Renal tumor necrosis factor-α and intercellular adhesion molecule-1 expression increased, and Cyp2c23 expression decreased in ANG/HS hypertension compared with the HS group, and CCR2b inhibition reduced tumor necrosis factor-α and intercellular adhesion molecule-1 and increased Cyp2c23 expression. Histological immunostaining revealed increased renal monocyte and macrophage infiltration in ANG/HS hypertensive rats with decreased infiltration in rats receiving RS102895 treatment. Albuminuria and cortical collagen staining also increased in ANG/HS hypertensive rats, and RS102895 treatment lowered these effects. Afferent arteriolar autoregulatory responses to increasing renal perfusion pressure were blunted in ANG/HS hypertension, and RS102895 treatment improved this response. These data suggest that CCR2b inhibition protects the kidney in hypertension by reducing inflammation and delaying the progression of hypertension.

AB - The present study was designed to determine whether chemokine receptor 2b (CCR2b) contributes to the development of renal injury in salt-sensitive angiotensin II (ANG) hypertension. Rats were infused with ANG and fed a high-salt diet (HS) for 14 days. Rats were divided into 4 groups: HS; HS administered the CCR2b antagonist, RS102895; Ang/HS hypertensive; and Ang/HS hypertensive administered RS102895. CCR2b inhibition slowed the progression of blood pressure elevation during the first week of ANG/HS hypertension; however, it did not alter blood pressure in the HS group. At 2 weeks, arterial pressure was not significantly different between ANG/HS and ANG/HS hypertensive rats administered RS102895. Renal cortical nuclear factor κB activity increased in ANG/HS hypertension compared with the HS group (0.11±0.006 versus 0.08±0.003 ng of activated nuclear factor κB per microgram of protein), and RS102895 treatment lowered nuclear factor κB activity in ANG/HS hypertension (0.08±0.005 ng of activated nuclear factor κB per microgram of protein). Renal tumor necrosis factor-α and intercellular adhesion molecule-1 expression increased, and Cyp2c23 expression decreased in ANG/HS hypertension compared with the HS group, and CCR2b inhibition reduced tumor necrosis factor-α and intercellular adhesion molecule-1 and increased Cyp2c23 expression. Histological immunostaining revealed increased renal monocyte and macrophage infiltration in ANG/HS hypertensive rats with decreased infiltration in rats receiving RS102895 treatment. Albuminuria and cortical collagen staining also increased in ANG/HS hypertensive rats, and RS102895 treatment lowered these effects. Afferent arteriolar autoregulatory responses to increasing renal perfusion pressure were blunted in ANG/HS hypertension, and RS102895 treatment improved this response. These data suggest that CCR2b inhibition protects the kidney in hypertension by reducing inflammation and delaying the progression of hypertension.

KW - Angiotensin

KW - CCR2b

KW - Chemokines

KW - Hypertension

KW - Inflammation

KW - Kidney

KW - MCP-1

UR - http://www.scopus.com/inward/record.url?scp=36448998082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448998082&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.107.098806

DO - 10.1161/HYPERTENSIONAHA.107.098806

M3 - Article

C2 - 17938380

AN - SCOPUS:36448998082

VL - 50

SP - 1069

EP - 1076

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 6

ER -